Wedbush Reiterates Outperform on Kura Oncology, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Kura Oncology (NASDAQ:KURA) and maintained a $40 price target.
October 18, 2023 | 2:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst has reiterated an Outperform rating on Kura Oncology and maintained a $40 price target.
The reiteration of an Outperform rating and a $40 price target by a Wedbush analyst is a positive signal for Kura Oncology. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100